Integral to the original intent of INTERMACSTM was contemporary alignment with ambulatory patients with advanced heart failure who were not currently receiving mechanical circulatory support devices. This mission will be fulfilled by the Medical Arm of Mechanically Assisted Circulatory Support, or MedaMACS, a prospective study of medically managed advanced heart failure patients.
MedaMACS will report the nature of optimal contemporary medical therapy for heart failure and provide information on medical outcomes in terms of timed endpoints of mechanical support, transplant, or death through two years of follow-up. Of equal weight will be the determination of functional capacity, quality of life, and satisfaction with therapy. These components of decision-making for advanced heart failure will be pivotal in moving toward the 21st century goal of patient-centered care with shared decision-making. The MedaMACS program will provide landmark data from which to refine selection for mechanical circulatory support from the ambulatory heart failure population within which the greatest benefit of mechanical support is anticipated.
Enrollment is set to begin in 12 participating advanced heart disease centers across the
Please check back for updates.